Bicycle Therapeutics plc Operating Lease, Payments
Bicycle Therapeutics plc (BCYC) reported Operating Lease, Payments of $2.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-07-30
- Bicycle Therapeutics plc operating lease, payments for the quarter ending 2026-06-30 was $943.00K, a 37.22% decline year-over-year.
- Bicycle Therapeutics plc operating lease, payments for the quarter ending 2026-03-31 was $1.52M, a 4.88% increase year-over-year.
- Bicycle Therapeutics plc operating lease, payments for the quarter ending 2025-12-31 was $1.50M, a 3.03% increase year-over-year.
- Bicycle Therapeutics plc operating lease, payments for the quarter ending 2025-09-30 was $1.50M, a 3.15% increase year-over-year.
- Bicycle Therapeutics plc operating lease, payments for fiscal 2025 was $5.96M, a 2.97% increase from fiscal 2024.
- Bicycle Therapeutics plc operating lease, payments for fiscal 2024 was $5.79M, a 3.40% increase from fiscal 2023.
- Bicycle Therapeutics plc operating lease, payments for fiscal 2023 was $5.59M, a 77.39% increase from fiscal 2022.
- Bicycle Therapeutics plc operating lease, payments for fiscal 2022 was $3.15M, a 246.21% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $943.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.47M 10-Q · filed 2026-07-30 | $3.96M derived: sum of 3 quarters · filed 2026-07-30 | $5.47M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $1.52M 10-Q · filed 2026-04-30 | $3.02M derived: sum of 2 quarters · filed 2026-04-30 | $4.53M derived: sum of 3 quarters · filed 2026-04-30 | $6.03M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $3.00M derived: sum of 2 quarters · filed 2026-03-17 | $4.50M derived: sum of 3 quarters · filed 2026-07-30 | $5.96M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $3.01M derived: sum of 2 quarters · filed 2026-07-30 | $4.46M 10-Q · filed 2025-10-30 | $5.91M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $2.96M 10-Q · filed 2026-07-30 | $4.41M derived: sum of 3 quarters · filed 2026-07-30 | $5.87M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $1.45M 10-Q · filed 2026-04-30 | $2.91M derived: sum of 2 quarters · filed 2026-04-30 | $4.37M derived: sum of 3 quarters · filed 2026-04-30 | $5.80M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.91M derived: sum of 2 quarters · filed 2026-03-17 | $4.35M derived: sum of 3 quarters · filed 2026-03-17 | $5.79M 10-K · filed 2026-03-17 |
| 2024-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.90M derived: sum of 2 quarters · filed 2025-10-30 | $4.33M 10-Q · filed 2025-10-30 | $5.74M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $2.87M 10-Q · filed 2025-08-08 | $4.28M derived: sum of 3 quarters · filed 2026-03-17 | $5.70M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $1.44M 10-Q · filed 2025-05-01 | $2.84M derived: sum of 2 quarters · filed 2026-03-17 | $4.26M derived: sum of 3 quarters · filed 2026-03-17 | $5.68M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $2.82M derived: sum of 2 quarters · filed 2026-03-17 | $4.24M derived: sum of 3 quarters · filed 2026-03-17 | $5.59M 10-K · filed 2026-03-17 |
| 2023-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.84M derived: sum of 2 quarters · filed 2024-10-31 | $4.19M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.77M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $1.35M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $3.15M 10-K · filed 2025-02-25 | |||
| 2021-12-31 | $911.00K 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |